Basis: FMP quote market capitalization / four-quarter operating cash flow. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/OCF ratio is N/A as of 2026-10-06T17:36:03.895Z.
Calculation as of: 2026-10-06T17:36:03.895Z.
Quote observation: 2026-10-06T17:34:19.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: ea268c636d02c1563f9a0cc17fa45ef3048b6802d4031696aa30e1bc9d7aaf2a
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/OCF RATIO
N/A
Connect Biopharma Holdings Limited
Market Cap
$59.34M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$61.35M
Price/OCF Ratio
N/A
TTM Avg
2.60
3Y Avg
2.60
5Y Avg
2.60
| NAME | MARKET CAP | PRICE/OCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Connect Biopharma Holdings Limited (CNTB) | $59.34M | N/A | N/A | N/A | N/A |
| Adicet Bio, Inc. (ACET)vs › | $59.66M | N/A | 93.25 | 93.25 | 93.25 |
| Oncolytics Biotech Inc. (ONCY)vs › | $59.86M | N/A | N/A | N/A | N/A |
| Boundless Bio, Inc. (BOLD)vs › | $59.33M | N/A | N/A | N/A | N/A |
| MiNK Therapeutics, Inc. (INKT)vs › | $59.16M | N/A | N/A | N/A | N/A |
| Fractyl Health, Inc. (GUTS)vs › | $60.29M | N/A | N/A | N/A | N/A |
| Kalaris Therapeutics Inc (KLRS)vs › | $61.17M | N/A | N/A | N/A | N/A |
| Talphera, Inc. (TLPH)vs › | $57.09M | N/A | N/A | N/A | N/A |
| Xilio Therapeutics, Inc. (XLO)vs › | $61.35M | N/A | 2.60 | 2.60 | 2.60 |
| OKYO Pharma Limited (OKYO)vs › | $56.78M | N/A | N/A | N/A | N/A |
P/OCF Ratio
N/A
P/FCF Ratio
N/A
P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
